Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C23H27FN2O |
| Molecular Weight | 366.4717 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCN(CC)C(=O)C1=CC=C(C=C1)C(=C2CCNCC2)C3=CC(F)=CC=C3
InChI
InChIKey=LPYYOHCTDGHYSI-UHFFFAOYSA-N
InChI=1S/C23H27FN2O/c1-3-26(4-2)23(27)19-10-8-17(9-11-19)22(18-12-14-25-15-13-18)20-6-5-7-21(24)16-20/h5-11,16,25H,3-4,12-15H2,1-2H3
| Molecular Formula | C23H27FN2O |
| Molecular Weight | 366.4717 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Tue Apr 01 18:12:52 GMT 2025
by
admin
on
Tue Apr 01 18:12:52 GMT 2025
|
| Record UNII |
F4DV6P2L7G
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
209807-53-4
Created by
admin on Tue Apr 01 18:12:52 GMT 2025 , Edited by admin on Tue Apr 01 18:12:52 GMT 2025
|
PRIMARY | |||
|
10570940
Created by
admin on Tue Apr 01 18:12:52 GMT 2025 , Edited by admin on Tue Apr 01 18:12:52 GMT 2025
|
PRIMARY | |||
|
F4DV6P2L7G
Created by
admin on Tue Apr 01 18:12:52 GMT 2025 , Edited by admin on Tue Apr 01 18:12:52 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
AZD5455, a Selective Enkephalinergic Agonist, in Rats and Dogs - AZD5455 is a selective enkephalinergic agonist being developed for the treatment of anxiety disorders. In this study, the pharmacokinetics, disposition and metabolism of AZD5455 in rats and dogs were reported. After intravenous administration, high systemic clearance was observed in rats (6.7 L/h/kg) and dogs (4.1 L/h/kg) with large volume distribution (18-26 and 11-14 L/kg for rats and dogs, respectively). The terminal half-life was 1.7-4.2 h and 2.9-3.5 h for rats and dogs, respectively. Moderate bioavailability was observed in rats (65-115%) and dogs (35-69%). Overall, the results from these studies suggested that AZD5455 was well absorbed and extensively metabolized through multiple pathways in these preclinical species.
|
||
|
ACTIVE MOIETY |
Materials sourced from abroad represent 90 to 95 percent of all materials used in production proposed for zone procedures. Inverted tariff savings will
initially result from the following bulk active ingredients, all subject to a 6.5% duty rate: AZD 0328 (HTSUS 2934.99.9000), AZD 5455(HTSUS 2933.39.9100) and AZD 4522 (HTSUS 2935.00.6000). Finished dose
products will be transferred to Site 1 for packaging and shipping.
|
